*.- The Duration of Response (DOR) was a median of 6.2 months in Sensitive patients, and a median of 5.3 months in the overall Population.
*.- ASCO has selected PharmaMar's abstract for an oral presentation on June 1st, where updated study data will be presented .
ASCO (American Society of Clinical Oncology) hasut published the data obtained in the study of lurbinectedin (PharmaMar - MSE:PHM) as
a single agent for the treatment of second line small cell lung cancer. These data will
be presented orally at the 19th Annual ASCO Congress, to be held from 31st May to 4
th June in Chicago (USA).
Lurbinectedin showed an Overall Response Rate (ORR) of 35.2% in the overall population and 46.6% and 21.3% in sensitive (CTFI 90 days, this meaning those Patients who have suffered a relapse of the disease in a period greater than or equal To 90 days) and resistant patients (CTFI<90 br="" days="" meaning="" patients="" this="" those="" who=""> have suffered a relapse of the disease in a period of less than 90 days), respectively.
<90 br="" days="" meaning="" patients="" this="" those="" who="">
The median Duration of Response (DOR) was 5.3 months in the overall population
and 6.2 and 4.7 months, respectively, in sensitive and resistant patients.
ASCO has selected PharmaMar's abstract for an oral presentation at its 19th Annual Congress.
The presentation will take place on 1st June at 1:15 PM (CST) during the Oral Abstract Session:
Universitario 12 de Octubre in Madrid and lead author of the study, will present Updated results of lurbinectedin as a single agent in second line small cell lung cancer.
In addition to the efficacy data, relevant safety data will also be presented.
Dr Paz-Ares and PharmaMar's management will organize a conference with investors
after the presentation of the data, information for which PharmaMar announce at a Later time.
The single-agent lurbinectedin study is a single-arm, Phase II, multicenter trial, involving 105 patients recruited from 39 centers in nine countries in Western Europe along with the USA, studying the safety and efficacy of lurbinectedin in second line Small cell lung cancer.
The conclusions of the abstract are that the data presented demonstrate that Lurbinectedin in monotherapy is active for the treatment of second-line small cell lung Cancer in both resistant and sensitive patients and has an acceptable and manageable Tolerability profile.
In addition, Dr. Paz-Ares says “After more than two decades of disappointments, Lurbinectedin is emerging as a potential new alternative treatment for second line Small cell lung cancer".
To be selected to present our data in an oral session at such an international Congress is an enormous honor and milestone for any Pharmaceutical company. These results show that lurbinectedin may have the potential to become a therapeutic Alternative for patients with small cell lung cancer, a pathology in which no second-line product has been approved for more than 20 years, so therefore, it is a unmet Medical need", says Luis Mora, General Manager of the Oncology Business Unit at PharmaMar.
Different studies with Yondelis® (trabectedin) will also be presented at the Congress.
The studies presented at the Congress are available at http://abstracts.asco.org.
***********************
Studies to be highlighted at ASCO 2019 .
Lurbinectedin :
*.- Efficacy and safety profile of lurbinectedin in second-line SCLC patients: results from a phase II single-agent trial.
(Abstract 8506).
Oral presentation: Saturday, 1st June 2019, from 1:15 PM to 4:15 PM in Hall
D2. Oral Abstract Session: Lung Cancer—Non-Small Cell Local-
Regional/Small Cell/Other Thoracic Cancers.
Firs Author: Luis G. Paz-Ares, MD., PhD., Hospital Universitario 12 de
Octubre, CiberOnc, Universidad Complutense and CNIO.
*********************
Yondelis® (trabectedin) :
*.- Trabectedin for recurrent WHO grade II or III meningioma:
A Randomized phase II study of the EORTC Brain Tumor Group .
(EORTC-1320-BTG). (Abstract 2007).
Oral Presentation: Monday, 3
rd June 2019, from 1:15 PM to 4:15 PM in
S102: Oral Abstract Session: Central Nervous System Tumors.
First Author: Matthias Preusser, MD., Medical University of Vienna,
Comprehensive Cancer Center.
*.- SAINT: Results of a phase 1/2 study of safety/efficacy using safe Amounts of ipilimumab, nivolumab, and trabectedin as first-line
treatment of advanced soft tissue sarcoma.
(Abstract 11016).
Poster Board: #339. Poster Discussion Session, Saturday, 1
st June 2019,
from 3:00 PM to 4:30 PM in S404, Hall A.
Fist Author: Erlinda Maria Gordon, MD., Sarcoma Oncology Research Center.
*.- Exploration of tumor genetic alterations and associations with Clinical outcomes: Retrospective genomic analysis of archived
liposarcoma (LPS) and leiomyosarcoma (LMS) samples from phase III trial of trabectedin (T) versus dacarbazine (D).
(Abstract 11019).
Poster Board: #342. Poster Discussion Session, Saturday, 1st June 2019,
from 3:00 PM to 4:30 PM in S404, Hall A.
First Author: Shibu Thomas, PhD., Janssen Research and Development.
*.- A Single-Center Retrospective Study Of Patients Treated With Trabectedin (TRB) with Long-Term Follow Up.
(Abstract 11061).
Poster Board: #384. Saturday, 1
st June 2019, from 8:00 AM to 11:00 AM, in
Hall A.
First Author: Brett Schroeder, MD., Fred Hutchinson Cancer Research Center
